EnteroMedics

ST. PAUL, MN -- (Marketwired) -- 05/22/13 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company will participate in the Craig-Hallum Annual Institutional Investor Conference in Minneapolis, Minnesota to take place ... read more

ST. PAUL, MN -- (Marketwired) -- 05/17/13 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company completed a pre-PMA (Premarket Approval) application meeting with the U.S. Food and Drug Administration (FDA) ... read more

ST. PAUL, MN -- (Marketwired) -- 04/22/13 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Wednesday, May 1, 2013 at 11:00 AM Eastern Time ... read more

ST. PAUL, MN -- (Marketwire) -- 03/12/13 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Greg S. Lea., EnteroMedics' Senior Vice President, Chief Financial Officer and Chief Operating Officer, is scheduled to ... read more

ST. PAUL, MN -- (Marketwire) -- 02/27/13 -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the closing of its previously announced public offering of 13,770,000 shares of its common stock and ... read more

ST. PAUL, MN -- (Marketwire) -- 02/26/13 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer, is scheduled to present at Cowen and ... read more

ST. PAUL, MN -- (Marketwire) -- 02/22/13 -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has priced an underwritten public offering of 13,770,000 shares of its common stock and warrants to ... read more

ST. PAUL, MN -- (Marketwire) -- 02/21/13 -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced its intention to offer, subject to market and other conditions, shares of its common stock and warrants to ... read more

ST. PAUL, MN -- (Marketwire) -- 02/20/13 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Senior Vice President and Chief Financial Officer Greg S. Lea has been appointed Chief Operating Officer. Consistent with ... read more

ST. PAUL, MN -- (Marketwire) -- 02/13/13 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months and full year ended December 31, 2012. For the full year ended ... read more

ST. PAUL, MN -- (Marketwire) -- 02/07/13 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced results from its randomized ReCharge Pivotal Trial of VBLOC® vagal blocking therapy for the treatment of obesity. The ... read more

ST. PAUL, MN -- (Marketwire) -- 11/19/12 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer, is scheduled to present at the Canaccord ... read more

ST. PAUL, MN -- (Marketwire) -- 11/15/12 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer, is scheduled to participate in a "fireside ... read more

ST. PAUL, MN -- (Marketwire) -- 11/07/12 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that hypertension data from a subgroup analysis of the EMPOWER trial were presented today at the American Heart ... read more

ST. PAUL, MN -- (Marketwire) -- 11/06/12 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer is scheduled to present at the ... read more

ST. PAUL, MN -- (Marketwire) -- 10/24/12 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three and nine months ended September 30, 2012. For the three months ended September 30, ... read more

ST. PAUL, MN -- (Marketwire) -- 10/17/12 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Wednesday, October 24, 2012 at 11:00 AM Eastern Time ... read more

ST. PAUL, MN -- (Marketwire) -- 10/04/12 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has obtained a committed issuer managed equity financing facility under which it may from time ... read more

ST. PAUL, MN -- (Marketwire) -- 09/20/12 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Greg S. Lea, SVP and Chief Financial Officer, is scheduled to present at the Craig-Hallum 3rd ... read more

ST. PAUL, MN -- (Marketwire) -- 09/11/12 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the company will participate in the Lazard Capital Markets Third Annual Medical Technology 1x1 Corporate Access ... read more